Cargando…

Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin

BACKGROUND: ERCC1, a component of nucleotide excision repair pathway, is known to repair DNA breaks induced by platinum drugs. We sought to ascertain if ERCC1 expression dynamics and a single nucleotide polymorphism (SNP) rs11615 are biomarkers of sensitivity to oxaliplatin therapy in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rao, Devika, Mallick, Atrayee Basu, Augustine, Titto, Daroqui, Cecilia, Jiffry, Jeeshan, Merla, Amartej, Chaudhary, Imran, Seetharam, Raviraja, Sood, Arjun, Gajavelli, Srikanth, Aparo, Santiago, Rajdev, Lakshmi, Kaubisch, Andreas, Chuy, Jennifer, Negassa, Abdissa, Mariadason, John M., Maitra, Radhashree, Goel, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756860/ https://www.ncbi.nlm.nih.gov/pubmed/31565185 http://dx.doi.org/10.18632/oncotarget.27140

Ejemplares similares

Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan
por: Maitra, Radhashree, et al.
Publicado: (2014)

Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer
por: Augustine, Titto, et al.
Publicado: (2022)

Targeted Therapy in Biliary Tract Cancers
por: Merla, Amartej, et al.
Publicado: (2015)

Immunotherapeutic advances in gastrointestinal malignancies
por: Rao, Devika, et al.
Publicado: (2019)

Telomere length regulation through epidermal growth factor receptor signaling in cancer
por: Augustine, Titto, et al.
Publicado: (2017)

Toll-like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer
por: Maitra, Radhashree, et al.
Publicado: (2017)

Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review
por: Merla, Amartej, et al.
Publicado: (2012)

Immune characterization of metastatic colorectal cancer patients post reovirus administration
por: Parakrama, Ruwan, et al.
Publicado: (2020)

ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
por: Baek, Moo-Jun
Publicado: (2015)

Model for End-Stage Liver Disease and Sodium Velocity Predicts Overall Survival in Nonmetastatic Hepatocellular Carcinoma Patients
por: Tang, Justin Y., et al.
Publicado: (2018)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
por: Acuna-Villaorduna, Ana, et al.
Publicado: (2022)

Neighborhood Variation in Rate of Revascularization among Acute Myocardial Infarction Patients in New York City
por: Negassa, Abdissa, et al.
Publicado: (2011)

Development and Characterization of a Genetic Mouse Model of KRAS Mutated Colorectal Cancer
por: Maitra, Radhashree, et al.
Publicado: (2019)

The Synergistic Role of Diet and Exercise in the Prevention, Pathogenesis, and Management of Ulcerative Colitis: An Underlying Metabolic Mechanism
por: Stavsky, Jonah, et al.
Publicado: (2019)

Prediction of Length of Stay Following Elective Percutaneous Coronary Intervention
por: Negassa, Abdissa, et al.
Publicado: (2011)

Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer
por: Baba, H, et al.
Publicado: (2012)

Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy
por: Chen, Jianfang, et al.
Publicado: (2016)

XPF–ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer
por: Huang, Ming-Yii, et al.
Publicado: (2023)

A WW-like module in the RAG1 N-terminal domain contributes to previously unidentified protein–protein interactions
por: Maitra, Radhashree, et al.
Publicado: (2009)

Oxaliplatin: pre-clinical perspectives on the mechanisms of action, response and resistance
por: Seetharam, RN, et al.
Publicado: (2009)

Noncoding RNA Profile in Reovirus Treated KRAS-Mutated Colorectal Cancer Patients
por: Saperstein, Rafael, et al.
Publicado: (2023)

Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer
por: Augustine, T A, et al.
Publicado: (2015)

Comparative Effectiveness of Biologic Agents Among Black and White Medicare Patients in the US With Metastatic Colorectal Cancer
por: Goel, Sanjay, et al.
Publicado: (2021)

Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil
por: Han, Jae Joon, et al.
Publicado: (2014)

The AKT/GSK3β-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1
por: Wei, Wei, et al.
Publicado: (2020)

Targeting Estrogens and Various Estrogen-Related Receptors against Non-Small Cell Lung Cancers: A Perspective
por: Maitra, Radhashree, et al.
Publicado: (2021)

Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis
por: Ma, Shou-Cheng, et al.
Publicado: (2015)

ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas
por: Orlandi, A., et al.
Publicado: (2015)

Molecular Tools for Metastatic Colorectal Cancer Characterization
por: Maitra, Radhashree, et al.
Publicado: (2020)

BRG1: Promoter or Suppressor of Cancer? The Outcome of BRG1’s Interaction with Specific Cellular Pathways
por: Shaykevich, Aaron, et al.
Publicado: (2023)

ERCC1 and ERCC2 Variants Predict Survival in Gastric Cancer Patients
por: Li, Yangkai, et al.
Publicado: (2013)

ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
por: Zaanan, Aziz, et al.
Publicado: (2014)

Transcriptome Signature of Immune Cells Post Reovirus Treatment in KRAS Mutated Colorectal Cancer
por: Fogel, Elisha J, et al.
Publicado: (2021)

Analysis of ERCC1 and ERCC2 gene variants in osteosarcoma, colorectal and breast cancer
por: GÓMEZ-DÍAZ, BENJAMÍN, et al.
Publicado: (2015)

The Association of ERCC1 and ERCC5 Polymorphisms with Lung Cancer Risk in Han Chinese
por: Lan, Xueling, et al.
Publicado: (2022)

Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells
por: Arango, D, et al.
Publicado: (2004)

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
por: Basso, M, et al.
Publicado: (2013)

ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
por: Li, P, et al.
Publicado: (2013)

Hepatoprotective effect of bone marrow-derived mesenchymal stromal cells in CCl(4)-induced liver cirrhosis
por: Aithal, Ashwini P., et al.
Publicado: (2021)

Expansion and characterization of bone marrow derived human mesenchymal stromal cells in serum-free conditions
por: Bhat, Samatha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_126vvo8ls2v88u5ab81ln0jglk